Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 ampli...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Fiona Turkes, Annette Bryant, Ruwaida Begum, Michael Davidson, Eleftheria Kalaitzaki, Maria Aresu, Retchel Lazaro-Alcausi, Jane Bryant, Isma Rana, Sue Chua, Lauren Aronson, Sanna Hulkki-Wilson, Charlotte Fribbens, David Watkins, Sheela Rao, Naureen Starling, David Cunningham, Irene Y. Chong, Ian Chau
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2022-03-01
Cyfres:Current Oncology
Pynciau:
oesophagogastric cancer
HER2
c-MYC
ibrutinib
Mynediad Ar-lein:https://www.mdpi.com/1718-7729/29/4/176
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg